[Variant Creutzfeld-Jakob disease (vCJD) : Epidemiology and prevention from human to human secondary transmission].
In the wake of the bovine spongiform encephalopathy (BSE) epidemic, variant Creutzfeldt-Jakob disease (vCJD) has emerged as a previously unknown prion disease of humans. The initial occurrence of vCJD was observed in 1995/1996, and, so far, a total of 219 vCJD cases have been reported worldwide from seven European and four non-European countries. Of these, 172 cases were observed in the United Kingdom. The exact prevalence of sub- or pre-clinical vCJD infections is unclear. Despite effective measures that have been implemented against both BSE in ruminants and its transmission to humans, there is now a theoretical risk of secondary vCJD transmissions from human to human, for example via blood and blood products, organs and tissues, or contaminated surgical instruments and medical devices. Four cases of probable vCJD transmissions via blood have been described, as well as one case of secondary infection via a plasma product. This article provides an overview of the surveillance and epidemiology of vCJD and outlines public health strategies for the risk assessment and risk management of this novel BSE-associated prion disease in humans.
Beekes
M
M
Transmissible Spongiforme Enzephalopathien, Robert Koch-Institut, Berlin. BeekesM@rki.de
D000818:Animals; D002417:Cattle; D007562:Creutzfeldt-Jakob Syndrome / Q000453:epidemiology* / Q000517:prevention & control* / Q000635:transmission; D004196:Disease Outbreaks / Q000517:prevention & control* / Q000706:statistics & numerical data*; D006801:Humans; D015994:Incidence; D011159:Population Surveillance; D011174:Portugal / Q000453:epidemiology; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors